That is a very good point. However, there is no comparison. Further, there is a great evolution in how the FDA conducts business, particularly when dealing with cellular medicine. The clinical trial turn around required delay periods for such treatments do & will continue to vary and differ from traditional, synthetic/chemical compounds.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.